Alfasigma USA Announces ZELNORMTM (tegaserod) Now Available for Treatment of Irritable Bowel Syndrome with Constipation
(World News USA)

BEDMINSTER, N.J.--(BUSINESS WIRE)--Aug 15, 2019-- Alfasigma USA, Inc. today announced that ZELNORMTM (tegaserod) is now available in the United States as a prescription pharmaceutical treatment for irritable bowel syndrome with constipation (IBS-C) in adult women less than 65 years of age. Alfasigma USA acquired ZELNORM from Sloan Pharma S.à r.l., a subsidiary of US WorldMeds Holdings, LLC, in July 2019. `We are pleased to inform U.S. physicians and pharmacists about the reintroduction of ZELNORM and how Alfasigma USA is supporting the availability, access to, and appropriate use of this important medicine for the many patients who cope daily with an urgent need for new treatment options,`...